ETFChannel.com
APLS Description — Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic compounds to treat diseases through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Pegcetacoplan targets C3, the central protein of the complement cascade. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Company Name: 
Apellis Pharmaceuticals Inc
Website: 
www.apellis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding APLS: 
33
Total Market Value Held by ETFs: 
$669,975,535.8
Total Market Capitalization: 
$5,472,000,000
% of Market Cap. Held by ETFs: 
12.24%
 ETF   APLS Weight   APLS Amount 
 VTI   0.01%   $143,068,915         
 VB   0.10%   $122,929,417         
 IWM   0.20%   $111,273,357         
 VBK   0.26%   $71,210,716         
 XBI   0.86%   $65,381,334         
 VXF   0.08%   $64,547,749         
 IWO   0.40%   $37,983,932         
 VHT   0.07%   $15,074,371         
 VTWO   0.20%   $11,817,421         
 PTH   2.36%   $5,363,054         
List of all 33 ETFs holding APLS »
Quotes delayed 20 minutes

Email EnvelopeFree APLS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.38 out of 4)
47th percentile
(ranked lower than approx. 53% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding APLS | Apellis Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.